THE Generic and Biosimilar Medicines Association (GBMA) has welcomed a positive PBAC recommendation for PBS listing of Renflexis, an infliximab biosimilar.
Renflexis joins Pfizer's Inflectra as the second biosimilar to inflixmab, with the GBMA saying Inflectra has gained only 3% market share in its first year, meaning Australia is yet to unlock the full value offered by biosimilars.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Dec 16
